RxDoctor Payments DataLook up a doctor →

Luis Gonzalez Gonzalez

Ophthalmology · Teaneck, NJNPI 1962816843

Payments from drug & device makers

$727,066in general payments, 2019–2025

Across 324 payments — averaging $2244.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$662K
  • Genentech USA, Inc.$44K
  • Welch Allyn$8K
  • Regeneron$7K
  • Alimera Sciences, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$826
  • plus $2K from 11 others
$15,627in research payments, 2019–2025

Across 14 payments — averaging $1116.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$16K

What the payments were for

  • Consulting fees$16,33528%
  • Speaking & faculty fees$32,53056%
  • Travel & lodging$4,7188%
  • Food & beverage$4,7038%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$727,066 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,769,160
Medicare patients
639
Services billed
21,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost35$14,047
ProlensaBromfenac Sodium31$13,012
Prednisolone Acetate308$11,098
RestasisCyclosporine12$9,879
Bromfenac Sodium39$5,054
Ketorolac Tromethamine167$4,228
Difluprednate21$2,237
FlarexFluorometholone Acetate14$1,730
ValacyclovirValacyclovir Hcl19$931
Brimonidine Tartrate53$922
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat69$889
Latanoprost130$795
Ofloxacin67$745
Dorzolamide Hcl53$687
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide11$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$131$23,92647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Teaneck

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →